Bon Natural Life Ltd BON
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.72
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.7M | $23.8M | $29.5M | $29.9M | $25.5M | $18.2M | $16.4M | — |
| Cost of revenue | $14.8M | $16.7M | $20.7M | $20.5M | $18.4M | $13.0M | $11.1M | — |
| Gross profit | $3.9M | $7.1M | $8.8M | $9.4M | $7.1M | $5.2M | $5.3M | — |
| R&D | $754.2K | $1.6M | $298.5K | $424.6K | $249.1K | $205.4K | $522.9K | — |
| SG&A | $4.3M | $3.3M | $2.3M | $2.2M | $1.3M | $1.4M | $1.3M | — |
| Total operating expenses | $5.5M | $5.2M | $2.9M | $2.8M | $1.7M | $1.7M | $2.1M | — |
| Operating income | -$1.6M | $1.9M | $5.9M | $6.6M | $5.4M | $3.5M | $3.2M | — |
| Interest expense | $366.2K | $303.3K | $238.2K | $446.9K | $417.3K | $329.1K | $333.2K | — |
| Pre-tax income | -$1.7M | $715.9K | $5.6M | $7.6M | $5.4M | $3.7M | $3.0M | — |
| Income tax | $339.4K | $351.2K | $1.0M | $1.3M | $820.9K | $556.3K | $427.2K | — |
| Net income | -$2.0M | $398.2K | $4.6M | $6.2M | $4.6M | $3.0M | $2.6M | — |
| EPS, basic | -0.72 | 4.17 | 125.72 | 7.47 | 0.69 | 0.58 | 0.50 | — |
| EPS, diluted | -0.72 | 4.14 | 124.92 | 7.43 | 0.68 | 0.58 | 0.50 | — |
| Shares, diluted (wtd. avg.) | 2.8M | 96,114 | 36,792 | 839,606 | 6.7M | 5.2M | 5.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.3M | $658.6K | $112.8K | $840.9K | $1.9M | $49.7K | — | — |
| Short-term investments | — | — | $65 | — | $1.7M | — | — | — |
| Receivables | $11.0M | $11.8M | $4.6M | $6.8M | $6.2M | $5.8M | — | — |
| Inventory | $3.3M | $1.6M | $987.3K | $1.7M | $1.6M | $1.0M | — | — |
| Total current assets | $45.8M | $39.8M | $24.2M | $14.7M | $16.5M | $10.8M | — | — |
| Property, plant and equipment | $18.2M | $15.0M | $15.5M | $21.6M | $19.2M | $14.2M | — | — |
| Other intangibles | $6.4M | $777.0K | $766.4K | $366.2K | $411.1K | $141.0K | — | — |
| Total assets | $85.2M | $61.8M | $46.6M | $37.3M | $36.4M | $25.2M | — | — |
| Accounts payable | $7.6M | $3.4M | $1.4M | $214.6K | $380.4K | $1.3M | — | — |
| Short-term debt | $1.1M | $461.8K | $419.6K | $2.1M | $448.0K | $1.2M | — | — |
| Total current liabilities | $26.3M | $16.4M | $9.6M | $6.6M | $7.5M | $11.7M | — | — |
| Long-term debt | $842.8K | $970.1K | $871.4K | $189.8K | $2.2M | $2.5M | — | — |
| Total liabilities | $27.2M | $17.4M | $10.6M | $7.2M | $9.9M | $14.2M | — | — |
| Retained earnings | $16.6M | $18.7M | $18.7M | $14.7M | $9.2M | $5.1M | — | — |
| Total equity | $57.6M | $43.9M | $36.0M | $30.1M | $26.5M | $11.0M | $7.3M | $4.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $141.1K | -$7.7M | -$616.9K | -$187.1K | $4.1M | $2.6M | $7.1M | — |
| Depreciation and amortisation | $1.0M | $1.1M | $945.5K | $210.9K | $228.5K | $230.6K | $226.6K | — |
| Stock-based compensation | $1.4M | $1.3M | $349.4K | $170.9K | $422.2K | $211.1K | — | — |
| Capital expenditure | $6.8K | $7.0K | $61.9K | $27.7K | $51.9K | $31.9K | $213.6K | — |
| Investing cash flow | -$10.0M | -$15.7K | -$1.2M | -$3.1M | -$7.4M | -$3.0M | -$8.4M | — |
| Financing cash flow | $15.5M | $8.8M | $1.2M | $2.3M | $5.4M | $112.5K | $804.7K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-003270.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $16.4M | $18.2M | $25.5M | $29.9M | $29.5M | $23.8M | $18.7M |
| Gross profit | — | $5.3M | $5.2M | $7.1M | $9.4M | $8.8M | $7.1M | $3.9M |
| Net income | — | $2.6M | $3.0M | $4.6M | $6.2M | $4.6M | $398.2K | -$2.0M |
Others in SIC 2833
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | $4.79B | — | — |
| TRLV | Trulieve Cannabis Corp. | $2.01B | — | -0.4% |
| CRON | Cronos Group Inc. | $1.23B | — | 24.6% |
| TLRY | Tilray Brands, Inc. | $382.7M | — | 11.5% |
| CGC | Canopy Growth Corp | $285.9M | — | — |
| USNA | USANA HEALTH SCIENCES INC | $257.9M | 24.1x | 8.3% |
| NAGE | Niagen Bioscience, Inc. | $192.3M | 12.2x | 29.9% |
| FTLF | FITLIFE BRANDS, INC. | $78.4M | 13.3x | 26.4% |